Subtitle
Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.
Subtitle
Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study.
Proto therapy Time
November 2020
Executive summary
22 patients with T1 to T2 N0M0 NSCLC received image-guided hypofractionated PBT to a total dose 48 GyRBE in 4 fractions for peripheral lesions and 60 GyRBE in 10 fractions for central lesions. The overall survival rates at 3 and 5 years were 81% and 49%. One patient (5%) developed a late grade 3 bronchial stricture requiring hospitalization and stent.
Key content topics
Top cancer treatments
Related contents
Webinar
18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
Proton Therapy Publication
July 2024
Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.
Proton Therapy Publication
July 2024
Initial experience and patient tolerance of proton stereotactic body radiotherapy.
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Webinar
March 29, 2023
Hypofractionation in Proton Therapy: radiobiological bases and clinical applications
Roberto
Orecchia
Barbara
Jereczek
Daniela
Alterio
Dante
Amelio
Jiri
Kubes
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Proton Therapy Publication
May 2022
The Role of Hypofractionation in Proton Therapy.
Proton Therapy Publication
April 2022
Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.